InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Discover the detailed record of transactions filed by Haft Nicholas, Director. Director active across 1 companies, notably Finch Therapeutics Group, Inc.. Cumulatively, 2 reports have been published. Total volume traded: €1.2m. The latest transaction was filed on 20 December 2021 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations2 total
€578,10463,850 shares@ €9.0541100.0% of flow
Common Stock, $0.001 par value per share
SEC:0001567619-21-022453·
Ideal exit: 16 Sept 2022 (T+270)
€578,10463,850 shares@ €9.05414.97% mcap50.0% of flow
Common Stock, $0.001 par value per share
SEC:0001567619-21-022453:0·
Ideal exit: 16 Sept 2022 (T+270)
2 of 2 declarations
About Haft Nicholas
Nicholas Haft is a Director at Finch Therapeutics Group, Inc. In this role, he participates in the governance of the company and strategic decision-making. His expertise in biotechnology is valuable for Finch Therapeutics, which develops innovative therapies.
